Cyclic AMP in Dendritic Cells: A Novel Potential Target for Disease-modifying Agents in Asthma and Other Allergic Disorders

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2020 May 7

PMID 32372523

Citations 8

Authors

Amy M Chinn

Paul A Insel

Affiliations

Soon will be listed here.

Abstract

Allergic diseases are immune disorders that are a global health problem, affecting a large portion of the world's population. Allergic asthma is a heterogeneous disease that alters the biology of the airway. A substantial portion of patients with asthma do not respond to conventional therapies; thus, new and effective therapeutics are needed. Dendritic cells (DCs), antigen presenting cells that regulate helper T cell differentiation, are key drivers of allergic inflammation but are not the target of current therapies. Here we review the role of dendritic cells in allergic conditions and propose a disease-modifying strategy for treating allergic asthma: cAMP-mediated inhibition of dendritic cells to blunt allergic inflammation. This approach contrasts with current treatments that focus on treating clinical manifestations of airway inflammation. Disease-modifying agents that target cAMP and its signalling pathway in dendritic cells may provide a novel means to treat asthma and other allergic diseases.

Citing Articles

Dendritic cell immunometabolism - a potential therapeutic target for allergic diseases.

Ouyang C, Huang J, Huang G, Wang Y Int J Med Sci. 2025; 22(2):417-431.

PMID: 39781535 PMC: 11704690. DOI: 10.7150/ijms.105532.

Crystallinity of covalent organic frameworks controls immune responses.

Esrafili A, Thumsi A, Jaggarapu M, Nile R, Kupfer J, Dugoni M Nat Commun. 2024; 15(1):9739.

PMID: 39528477 PMC: 11555212. DOI: 10.1038/s41467-024-54227-9.

Meteorin-like protein/METRNL/Interleukin-41 ameliorates atopic dermatitis-like inflammation.

Huang D, Liu X, Gao X, Choi C, Giglio G, Farah L Allergy. 2024; 80(2):474-488.

PMID: 38727640 PMC: 11804313. DOI: 10.1111/all.16150.

ITGB1 alleviates osteoarthritis by inhibiting cartilage inflammation and apoptosis via activating cAMP pathway.

Xie L, Li Z, Chen Z, Li M, Tao J J Orthop Surg Res. 2023; 18(1):849.

PMID: 37941009 PMC: 10634155. DOI: 10.1186/s13018-023-04342-y.

Modulation of Human Dendritic Cell Functions by Phosphodiesterase-4 Inhibitors: Potential Relevance for the Treatment of Respiratory Diseases.

Nguyen H, Tiberio L, Facchinetti F, Ripari G, Violi V, Villetti G Pharmaceutics. 2023; 15(9).

PMID: 37765223 PMC: 10535230. DOI: 10.3390/pharmaceutics15092254.

References

Helft J, Bottcher J, Chakravarty P, Zelenay S, Huotari J, Schraml B . GM-CSF Mouse Bone Marrow Cultures Comprise a Heterogeneous Population of CD11c(+)MHCII(+) Macrophages and Dendritic Cells. Immunity. 2015; 42(6):1197-211. DOI: 10.1016/j.immuni.2015.05.018. View

Aronoff D, Canetti C, Serezani C, Luo M, Peters-Golden M . Cutting edge: macrophage inhibition by cyclic AMP (cAMP): differential roles of protein kinase A and exchange protein directly activated by cAMP-1. J Immunol. 2005; 174(2):595-9. DOI: 10.4049/jimmunol.174.2.595. View

Beltejar M, Lau H, Golkowski M, Ong S, Beavo J . Analyses of PDE-regulated phosphoproteomes reveal unique and specific cAMP-signaling modules in T cells. Proc Natl Acad Sci U S A. 2017; 114(30):E6240-E6249. PMC: 5544305. DOI: 10.1073/pnas.1703939114. View

Green R, Brightling C, Bradding P . The reclassification of asthma based on subphenotypes. Curr Opin Allergy Clin Immunol. 2007; 7(1):43-50. DOI: 10.1097/ACI.0b013e3280118a32. View

MacGlashan Jr D, Bochner B, Adelman D, Jardieu P, Togias A, McKenzie-White J . Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997; 158(3):1438-45. View

Simpson C, Newton J, Hippisley-Cox J, Sheikh A . Incidence and prevalence of multiple allergic disorders recorded in a national primary care database. J R Soc Med. 2008; 101(11):558-63. PMC: 2586863. DOI: 10.1258/jrsm.2008.080196. View

Trian T, Burgess J, Niimi K, Moir L, Ge Q, Berger P . β2-Agonist induced cAMP is decreased in asthmatic airway smooth muscle due to increased PDE4D. PLoS One. 2011; 6(5):e20000. PMC: 3096656. DOI: 10.1371/journal.pone.0020000. View

Mastelic-Gavillet B, Balint K, Boudousquie C, Gannon P, Kandalaft L . Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results. Front Immunol. 2019; 10:766. PMC: 6470191. DOI: 10.3389/fimmu.2019.00766. View

Jackson M . Asthma, illness, and identity. Lancet. 2008; 372(9643):1030-1. DOI: 10.1016/s0140-6736(08)61429-4. View

10.

Vollmer W, Osborne M, Buist A . 20-year trends in the prevalence of asthma and chronic airflow obstruction in an HMO. Am J Respir Crit Care Med. 1998; 157(4 Pt 1):1079-84. DOI: 10.1164/ajrccm.157.4.9704140. View

11.

Shabb J . Physiological substrates of cAMP-dependent protein kinase. Chem Rev. 2001; 101(8):2381-411. DOI: 10.1021/cr000236l. View

12.

Fassbender M, Gerlitzki B, Ullrich N, Lupp C, Klein M, Radsak M . Cyclic adenosine monophosphate and IL-10 coordinately contribute to nTreg cell-mediated suppression of dendritic cell activation. Cell Immunol. 2010; 265(2):91-6. DOI: 10.1016/j.cellimm.2010.07.007. View

13.

Samitas K, Delimpoura V, Zervas E, Gaga M . Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives. Eur Respir Rev. 2015; 24(138):594-601. PMC: 9487615. DOI: 10.1183/16000617.00001715. View

14.

Lipscomb M, Masten B . Dendritic cells: immune regulators in health and disease. Physiol Rev. 2002; 82(1):97-130. DOI: 10.1152/physrev.00023.2001. View

15.

Copsel S, Garcia C, Diez F, Vermeulem M, Baldi A, Bianciotti L . Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation. J Biol Chem. 2011; 286(9):6979-88. PMC: 3044954. DOI: 10.1074/jbc.M110.166868. View

16.

Torkildsen O, Myhr K, Bo L . Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol. 2015; 23 Suppl 1:18-27. PMC: 4670697. DOI: 10.1111/ene.12883. View

17.

Aandahl E, Moretto W, Haslett P, Vang T, Bryn T, Tasken K . Inhibition of antigen-specific T cell proliferation and cytokine production by protein kinase A type I. J Immunol. 2002; 169(2):802-8. DOI: 10.4049/jimmunol.169.2.802. View

18.

Djukanovic R, Wilson S, Kraft M, Jarjour N, Steel M, Chung K . Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004; 170(6):583-93. DOI: 10.1164/rccm.200312-1651OC. View

19.

Tajiri T, Niimi A, Matsumoto H, Ito I, Oguma T, Otsuka K . Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study. Ann Allergy Asthma Immunol. 2014; 113(4):470-5.e2. DOI: 10.1016/j.anai.2014.06.004. View

20.

Insel P, Wilderman A, Zambon A, Snead A, Murray F, Aroonsakool N . G Protein-Coupled Receptor (GPCR) Expression in Native Cells: "Novel" endoGPCRs as Physiologic Regulators and Therapeutic Targets. Mol Pharmacol. 2015; 88(1):181-7. PMC: 4468643. DOI: 10.1124/mol.115.098129. View